Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Division of Geriatrics, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Syst Rev. 2021 Mar 11;10(1):73. doi: 10.1186/s13643-021-01624-6.
The coronavirus disease 2019 (COVID-19) pandemic has caused recurring and major outbreaks in multiple human populations around the world. The plethora of clinical presentations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been described extensively, of which olfactory dysfunction (OD) was established as an important and common extrapulmonary manifestation of COVID-19 infection. The aim of this protocol is to conduct a systematic review and meta-analysis on peer-reviewed articles which described clinical data of OD in COVID-19 patients.
This research protocol has been prospectively registered with the Prospective Register of Systematic Reviews (PROSPERO; CRD42020196202). CINAHL, ClinicalTrials.gov, Cochrane Central, EMBASE, MEDLINE and PubMed, as well as Chinese medical databases China National Knowledge Infrastructure (CNKI), VIP and WANFANG, will be searched using keywords including 'COVID-19', 'coronavirus disease', '2019-nCoV', 'SARS-CoV-2', 'novel coronavirus', 'anosmia', 'hyposmia', 'loss of smell', and 'olfactory dysfunction'. Systematic review and meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines. Articles will be screened according to pre-specified inclusion and exclusion criteria to extract studies that include new clinical data investigating the effect of COVID-19 on olfactory dysfunction. Included articles will be reviewed in full; data including patient demographics, clinical characteristics of COVID-19-related OD, methods of olfactory assessment and relevant clinical outcomes will be extracted. Statistical analyses will be performed using the Comprehensive Meta-Analysis version 3.
This systematic review and meta-analysis protocol will aim to collate and synthesise all available clinical evidence regarding COVID-19-related OD as an important neurosensory dysfunction of COVID-19 infection. A comprehensive search strategy and screening process will be conducted to incorporate broad clinical data for robust statistical analyses and representation. The outcome of the systematic review and meta-analysis will aim to improve our understanding of the symptomatology and clinical characteristics of COVID-19-related OD and identify knowledge gaps in its disease process, which will guide future research in this specific neurosensory defect.
PROSPERO registration number: CRD42020196202.
2019 年冠状病毒病（COVID-19）大流行在全球多个人群中反复引发了重大疫情。严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的临床表现繁多，其中嗅觉功能障碍（OD）被确定为 COVID-19 感染的一种重要且常见的肺外表现。本方案的目的是对描述 COVID-19 患者 OD 临床数据的同行评审文章进行系统评价和荟萃分析。
本研究方案已在前瞻性系统评价注册中心（PROSPERO；CRD42020196202）进行了前瞻性注册。将使用关键词“COVID-19”、“冠状病毒病”、“2019-nCoV”、“SARS-CoV-2”、“新型冠状病毒”、“anosmia”、“hyposmia”、“嗅觉丧失”和“嗅觉功能障碍”，在 CINAHL、ClinicalTrials.gov、Cochrane 中央、EMBASE、MEDLINE 和 PubMed 以及中国医学数据库中国知网（CNKI）、维普和万方进行检索，以搜索相关文献。将根据系统评价和荟萃分析首选报告项目（PRISMA）和观察性研究荟萃分析（MOOSE）指南进行系统评价和荟萃分析。根据预先设定的纳入和排除标准筛选文章，以提取包括新的临床数据调查 COVID-19 对嗅觉功能障碍影响的研究。将对纳入的文章进行全面审查；提取患者人口统计学、COVID-19 相关 OD 的临床特征、嗅觉评估方法和相关临床结局等数据。将使用 Comprehensive Meta-Analysis version 3 进行统计分析。
本系统评价和荟萃分析方案旨在收集和综合 COVID-19 相关 OD 的所有现有临床证据，OD 是 COVID-19 感染的一种重要神经感觉功能障碍。将进行广泛的搜索策略和筛选过程，以纳入广泛的临床数据进行稳健的统计分析和代表性。系统评价和荟萃分析的结果旨在提高我们对 COVID-19 相关 OD 的症状和临床特征的理解，并确定其疾病过程中的知识空白，这将指导该特定神经感觉缺陷的未来研究。
PROSPERO 注册号：CRD42020196202。
Zotero 插件